CA-FUJIREBIO/ARIBIO
8.3.2023 13:31:39 CET | Business Wire | Press release
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study launched by AriBio in Dec. 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005122/en/
AriBio completed a Phase 2 study in 2021 in mild to moderate Alzheimer’s disease patients with their lead compound AR1001, a PDE5 inhibitor with preclinical efficacy shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity, and stimulate autophagy activity to remove toxic proteins. The Phase 3 study in patients with early Alzheimer’s disease, AR1001-ADP3-US01, has been launched in the United States and plans to expand to other countries in 2023.
Fujirebio, a trusted partner for high-quality IVD testing solutions and a pioneer in neurodegenerative disease diagnostics is committed to the advancement of biomarkers to improve diagnosis of Alzheimer’s disease. Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease testing and the first to receive FDA authorization in 2022 for its Lumipulse® G β-Amyloid Ratio (1-42/ 1-40) test. Fujirebio continues to make advances in the field to provide fully automated blood-based tests for Alzheimer’s disease and other neurological disorders.
“AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration. Fujirebio is an ideal partner for us and reflects our commitment to advancements in this space. We look forward to working closely with Fujirebio to improve the detection of Alzheimer’s disease and other neurodegenerative diseases with their pioneering assays,” commented James Rock, President of AriBio Co., Ltd US Office.
“Fujirebio continues to lead the industry in the development of high quality, functional tests to improve clinicians’ ability to detect and diagnose a variety of neurodegenerative conditions. We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools,” stated Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
About Fujirebio
Fujirebio Diagnostics, Inc., a wholly owned subsidiary of H.U. Group Holdings, Inc. and Fujirebio Holdings, Inc., is a premier diagnostics company and the industry leader in cancer biomarker tests. Fujirebio Diagnostics specializes in the contract development and manufacturing for the diagnostics industry leaders and market development of novel in-vitro diagnostic products for the management of human disease states. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at www.fujirebio.com. H.U. Group Holdings, Inc. (formerly known as Miraca Holdings Inc.) is a listed company on the Tokyo Stock Exchange – TYO: 4544.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005122/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom